https://www.nasdaq.com/press-release/aikido-pharma-announces-dr.-rachel-yehudas-appearance-on-cbs-news-2022-01-05
https://www.nasdaq.com/press-release/datchat-appoints-mark-mathis-as-chief-blockchain-architect-to-lead-web-3.0
https://www.nasdaq.com/press-release/aikido-pharma-reports-filing-for-expanded-worldwide-patent-coverage-on-key-assets
https://www.nasdaq.com/press-release/aikido-pharma-announces-strategic-interest-in-asp-isotopes-inc.-2021-12-06
https://www.nasdaq.com/press-release/datchat-launches-rewards-program-2021-11-30
https://www.nasdaq.com/press-release/datchat-announces-sponsorship-of-the-breakfast-club-2021-11-12
https://www.nasdaq.com/press-release/c-o-r-r-e-c-t-i-o-n-aikido-pharma-inc.-2021-11-12
https://www.nasdaq.com/press-release/datchat-ceo-darin-myman-to-speak-at-dcentral-miami-and-will-be-an-emerald-sponsor-of
https://www.nasdaq.com/press-release/datchat-launches-social-network-privacy-platform-2021-10-28
https://www.nasdaq.com/press-release/datchat-to-run-national-marketing-campaign-on-barstool-sports-2021-10-15
https://www.nasdaq.com/press-release/aikido-pharma-secures-interest-in-electric-truck-maker-tevva-motors-ltd-2021-09-28
https://www.nasdaq.com/press-release/datchat-announces-partnership-and-influencer-campaign-with-izea-2021-09-22
https://www.nasdaq.com/press-release/aikido-pharma-secures-interest-in-growing-tele-health-company-2021-09-20
https://www.nasdaq.com/press-release/aikido-pharma-releases-shareholder-update-near-term-catalysts-approaching-2021-09-14
https://www.nasdaq.com/press-release/datchat-announces-exhibit-participation-at-propelify-innovation-festival-on-october-6
https://www.nasdaq.com/press-release/datchat-announces-gold-partner-status-for-the-blockchain-expo-north-america-2021-09
https://www.nasdaq.com/press-release/datchat-to-present-at-the-10th-annual-gateway-conference-on-september-8-2021-2021-08
https://www.nasdaq.com/press-release/datchat-partners-with-rutgers-university-computer-science-through-industry-affiliates
https://www.nasdaq.com/press-release/aikido-provides-update-on-use-of-machine-learning-in-drug-development-program-2021-08
https://www.nasdaq.com/press-release/notice-of-allowance-issued-for-central-nervous-system-peptide-technology-2021-07-27
https://www.nasdaq.com/press-release/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland
https://www.nasdaq.com/press-release/aikido-pharma-to-attend-the-alzheimers-association-international-conference-2021-07
https://www.nasdaq.com/press-release/aikido-pharma-files-patent-application-for-the-use-of-ketamine-to-treat-alzheimers
https://www.nasdaq.com/press-release/aikido-pharma-announces-positive-phase-1-data-presented-at-asco-on-225ac-j591-2021-06
https://www.nasdaq.com/press-release/aikido-pharma-has-pending-data-results-on-june-4th-with-strongest-balance-sheet-in
https://www.nasdaq.com/press-release/aikido-pharma-announces-phase-1-data-to-be-presented-at-the-american-society-of
https://www.nasdaq.com/press-release/aiki-featured-as-stock-to-watch-ahead-of-significant-key-milestones-2021-05-19
https://www.nasdaq.com/press-release/aikido-pharma-inc.%3a-invitation-to-the-q2-virtual-investor-summit-2021-05-13
https://www.nasdaq.com/press-release/aikis-near-term-catalyst-approaching-this-quarter-with-strong-cash-balance-sheet-for
https://www.nasdaq.com/press-release/aikido-pharma-inc.-to-present-at-the-benzinga-global-small-cap-conference-the
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-first-quarter-2021-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-participation-in-the-benzinga-global-small-cap
https://www.nasdaq.com/press-release/aikido-pharma-announces-dr.-rachel-yehudas-appearance-at-sxsw-2021-04-27
https://www.nasdaq.com/press-release/aikido-pharma-announces-inventor-and-scientist-dr.-matthew-frieman-joins-scientific
https://www.nasdaq.com/press-release/aikido-pharma-announces-withdrawal-of-s-1-registration-statement-2021-04-22
https://www.nasdaq.com/press-release/aikido-pharma-notes-advancement-in-radiopharmaceutical-research-2021-04-16
https://www.nasdaq.com/press-release/aikido-granted-sublicense-to-technology-for-targeted-psilocybin-treatment-of-neuro
https://www.nasdaq.com/press-release/aikido-pharma-provides-business-update-2021-04-05
https://www.nasdaq.com/press-release/aikido-pharma-sponsors-psychedelic-compound-research-to-treat-ptsd-2021-03-29
https://www.nasdaq.com/press-release/aikido-pharma-announces-dr.-matt-friemans-appearance-on-this-week-in-virology-2021-03
https://www.nasdaq.com/press-release/aikido-pharma-inc.-updates-announcement-of-webcast-link-for-the-h.c.-wainwright
https://www.nasdaq.com/press-release/aikido-pharma-inc.-to-present-at-the-h.c.-wainwright-global-life-sciences-conference
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-exercise-of-option-to-purchase-additional-shares-in
https://www.nasdaq.com/press-release/aikido-pharma-provides-update-on-its-antiviral-platform-including-the-virus-that
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-closing-of-%2475-million-bought-deal-offering-of-common
https://www.nasdaq.com/press-release/aikido-pharma-inc.-increases-previously-announced-bought-deal-offering-of-common
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-%2410-million-bought-deal-offering-of-common-stock-2021-02
https://www.nasdaq.com/press-release/aikido-pharma-enters-into-letter-of-intent-with-silo-pharma-for-use-of-psilocybin-and
https://www.nasdaq.com/press-release/aikido-pharma-appoints-dr.-scott-t.-tagawa-m.d.-to-scientific-advisory-board-2021-02
https://www.nasdaq.com/press-release/aikido-pharma-adds-inventor-dr.-neil-h.-bander-m.d.-to-scientific-advisory-board-2021
https://www.nasdaq.com/press-release/aikido-pharma-secures-early-interest-in-next-generation-radiotherapy-2021-02-01
https://www.nasdaq.com/press-release/aikido-pharma-inc.-regains-compliance-with-nasdaq-listing-requirements-2021-01-22
https://www.nasdaq.com/press-release/aikido-pharma-inc.-executes-licensing-agreement-for-psilocybin-for-cancer
https://www.nasdaq.com/press-release/aikido-pharma-announces-publication-of-artificial-intelligence-machine-learning
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-results-of-2020-annual-stockholder-meeting-2020-11-20
https://www.nasdaq.com/press-release/voltron-therapeutics-inc.-to-participate-in-the-2020-fall-defense-techconnect-virtual
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-publication-of-favorable-peer-reviewed-study-of-newly
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-positive-statistically-significant-proof-of-concept
https://www.nasdaq.com/press-release/hoth-therapeutics-provides-update-for-novel-covid-19-therapeutic-on-the-go-sars-cov-2
https://www.nasdaq.com/press-release/aikido-pharma-inc.-provides-update-on-its-next-generation-chemotherapeutic-treatment
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-uspto-grant-of-patent-for-targeted-13-cis-ramba
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-its-ht-003-shows-positive-initial-data-inhibiting-toll
https://www.nasdaq.com/press-release/sidoti-virtual-investor-conference-2020-09-22
https://www.nasdaq.com/press-release/hoth-therapeutics-enters-into-sponsored-research-agreement-for-on-the-go-covid-19
https://www.nasdaq.com/press-release/aikido-pharma-announces-update-on-its-use-of-artificial-intelligence-2020-09-18
https://www.nasdaq.com/press-release/voltron-therapeutics-inc.-executes-manufacturing-agreement-with-global-pharmaceutical
https://www.nasdaq.com/press-release/voltron-therapeutics-inc.-announces-completion-of-first-small-animal-safety-and
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-participation-at-the-h.c.-wainwright-22nd-annual-global
https://www.nasdaq.com/press-release/aikido-pharma-announces-peer-reviewed-publication-of-positive-results-from-study-of
https://www.nasdaq.com/press-release/hoth-therapeutics-chief-scientific-officer-dr.-stefanie-johns-to-appear-on-one
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/hoth-therapeutics-appoints-stefanie-johns-ph.d.-as-chief-scientific-officer-2020-08
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-participation-at-upcoming-investor-conferences-in
https://www.nasdaq.com/press-release/laidlaw-venture-partners-hosts-panel-discussion-cutting-edge-perspectives-on-the
https://www.nasdaq.com/press-release/hoth-therapeutics-provides-shareholder-update-on-covid-19-initiatives-and
https://www.nasdaq.com/press-release/aikido-pharma-sponsors-survival-study-of-university-of-kentucky-anticancer-drug-g4-1
https://www.nasdaq.com/press-release/aikido-pharma-inc.-to-present-at-the-ld-500-virtual-conference-2020-08-14
https://www.nasdaq.com/press-release/hoth-therapeutic-announces-that-it-has-submitted-its-request-to-australia-ethics
https://www.nasdaq.com/press-release/option-for-treatment-for-coronavirus-extended-2020-08-11
https://www.nasdaq.com/press-release/hoth-therapeutics-to-participate-in-ld-micros-zooming-with-ld-august-11th-8-am-pdt
https://www.nasdaq.com/press-release/hoth-therapeutics-licenses-intellectual-property-to-develop-real-time-breath-based
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/aikido-pharma-inc.-regains-compliance-with-nasdaq-listing-requirements-2020-08-03
https://www.nasdaq.com/press-release/hoth-therapeutics-executes-licensing-agreement-of-vnlg-152-for-treatment-of
https://www.nasdaq.com/press-release/registration-for-sidotis-2020-fall-virtual-investor-conference-is-now-open-2020-07-30
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-key-progress-in-computational-approaches-to-identify
https://www.nasdaq.com/press-release/voltron-therapeutics-retains-buenaventura-advisors-llc-to-explore-strategic
https://www.nasdaq.com/press-release/voltron-therapeutics-inc.-initiates-animal-testing-of-self-assembling-vaccine-in
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-sponsored-research-agreement-with-vcu-for-potential-covid
https://www.nasdaq.com/press-release/aikido-pharma-inc.-provides-update-to-machine-learning-pancreatic-cancer-research
https://www.nasdaq.com/press-release/hoth-therapeutics-enters-into-expanded-sponsored-research-agreement-with-the-george
https://www.nasdaq.com/press-release/hoth-therapeutics-scientific-advisory-board-member-and-inventor-of-licensed-novel
https://www.nasdaq.com/press-release/hoth-therapeutics-receives-notice-of-allowance-for-u.s.-patent-regarding-methods-for
https://www.nasdaq.com/press-release/hoth-therapeutics-provides-shareholder-update-on-therapeutics-pipeline-2020-06-03
https://www.nasdaq.com/press-release/aikido-pharma-announces-publication-of-results-from-sponsored-research-at-wake-forest
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-closing-of-public-offering-of-common-stock-2020-05-27
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-the-appointment-of-michael-peters-ph.d.-to-scientific
https://www.nasdaq.com/press-release/hoth-announces-pricing-of-public-offering-of-shares-of-common-stock-2020-05-21
https://www.nasdaq.com/press-release/hoth-announces-proposed-public-offering-of-common-stock-2020-05-21
https://www.nasdaq.com/press-release/hoth-therapeutics-licenses-novel-peptide-covid-19-therapeutic-2020-05-20
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-distribution-of-hoth-dividend-2020-05-19
https://www.nasdaq.com/press-release/aikido-pharma-inc.-provides-update-on-distribution-date-for-hoth-dividend
https://www.nasdaq.com/press-release/aikido-pharma-executes-artificial-intelligence-and-machine-learning-research
https://www.nasdaq.com/press-release/hoth-therapeutics-expands-partnership-with-zylo-therapeutics-inc.-2020-05-05
https://www.nasdaq.com/press-release/aikido-pharma-inc.-provides-update-on-anticipated-distribution-date-for-hoth-dividend
https://www.nasdaq.com/press-release/notice-of-record-date-of-hoth-distribution-2020-04-30
https://www.nasdaq.com/press-release/hoth-therapeutics-inc.-voltron-therapeutics-inc.-halovax-announce-selection-of-the
https://www.nasdaq.com/press-release/hoth-therapeutics-to-host-shareholder-update-conference-call-with-dr.-mark-poznansky
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-top-line-preclinical-data-from-cutaneous-lupus
https://www.nasdaq.com/press-release/aikido-pharma-executes-licensing-agreement-with-university-of-maryland-for-antiviral
https://www.nasdaq.com/press-release/aikido-pharma-inc.-sets-record-date-for-hoth-distribution-2020-04-20
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-additions-to-its-board-of-directors-2020-04-17
https://www.nasdaq.com/press-release/dr.-mark-poznansky-co-creator-of-vaxcelerate-appeared-on-msnbc-to-discuss-covid-19
https://www.nasdaq.com/press-release/aikido-pharma-inc.-announces-%2414.0-million-registered-direct-offering-priced-at-the
https://www.nasdaq.com/press-release/aikido-pharma-executes-exclusive-world-wide-license-to-broad-spectrum-antiviral-drug
https://www.nasdaq.com/press-release/hoth-therapeutics-commences-next-phase-of-vnlg-152-study-2020-04-09
https://www.nasdaq.com/press-release/hoth-update-on-halovax-partnership-vaccine-to-fight-covid-19-with-sponsored-research
https://www.nasdaq.com/press-release/hoth-therapeutics-enters-into-letter-of-intent-with-isoprene-pharmaceuticals-inc.-to
https://www.nasdaq.com/press-release/aikido-pharma-inc.-provides-update-on-timing-of-record-date-and-anticipated
https://www.nasdaq.com/press-release/aikido-issues-shareholder-update-on-covid-19-dividend-and-path-forward-2020-03-26
https://www.nasdaq.com/press-release/emerging-markets-report%3a-hoth-therapeutics-is-working-on-a-potential-coronavirus
https://www.nasdaq.com/press-release/hoth-announces-pricing-of-%245-million-public-offering-of-common-stock-2020-03-24
https://www.nasdaq.com/press-release/aikido-pharma-inc.-adopts-plan-to-preserve-valuable-tax-assets-2020-03-23
https://www.nasdaq.com/press-release/hoth-therapeutics-inc.-announces-proposed-public-offering-of-common-stock-2020-03-23
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-agreement-to-joint-development-of-a-self-assembling
https://www.nasdaq.com/press-release/aikido-pharma-adds-artificial-intelligence-leader-to-advisory-board-2020-03-20
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-positive-preclinical-data-of-weg232-treatment-developed
https://www.nasdaq.com/press-release/shareholder-update-from-aikido-pharma-incorporated-on-coronavirus-option-2020-03-18
https://www.nasdaq.com/press-release/diamond-equity-research-publishes-report-valuing-hoth-common-stock-at-%247.00-per-share
https://www.nasdaq.com/press-release/shareholder-update-on-treatment-for-coronavirus-optioned-by-spherix-2020-03-10
https://www.nasdaq.com/press-release/spherix-announces-%245.75-million-registered-direct-offering-priced-at-the-market-2020
https://www.nasdaq.com/press-release/hoth-therapeutics-inc.-states-covid-19-coronavirus-poses-no-negative-effect-on
https://www.nasdaq.com/press-release/treatment-for-coronavirus-optioned-by-spherix-2020-03-06
https://www.nasdaq.com/press-release/spherix-incorporated-changing-name-to-aikido-pharma-inc.-to-reflect-increased-focus
https://www.nasdaq.com/press-release/spherix-moves-dividend-record-date-to-friday-march-6-2020-2020-03-04
https://www.nasdaq.com/press-release/spherix-executes-machine-learning-scientific-research-agreement-2020-03-03
https://www.nasdaq.com/press-release/spherix-announces-pricing-of-%247.5-million-public-offering-2020-03-03
https://www.nasdaq.com/press-release/spherix-attends-artificial-intelligence-and-machine-learning-pharmaceutical
https://www.nasdaq.com/press-release/spherix-announces-a-special-dividend-distribution-2020-02-23
https://www.nasdaq.com/press-release/hoth-therapeutics-receives-notice-of-allowance-from-european-patent-office-2020-02-19
https://www.nasdaq.com/press-release/spherix-issues-letter-to-shareholders-2020-02-14
https://www.nasdaq.com/press-release/hoth-therapeutics-announces-positive-preliminary-preclinical-data-on-its-therapeutic
https://www.nasdaq.com/press-release/hoth-therapeutics-inc.-to-present-at-2020-noble-capital-markets-sixteenth-annual
https://www.nasdaq.com/press-release/hoth-initiates-preclinical-gene-therapy-program-with-nc-state-for-the-treatment-of
https://www.nasdaq.com/press-release/hoth-therapeutics-to-further-its-research-of-vnlg-152-and-plans-exercise-of-its
https://www.nasdaq.com/press-release/spherix-launches-newly-redesigned-website-2020-01-21
https://www.nasdaq.com/press-release/hoth-completes-animal-safety-study-of-proprietary-biolexa-platform-for-the-treatment
https://www.nasdaq.com/press-release/emerging-markets-report%3a-a-very-big-deal-2020-01-17
https://www.nasdaq.com/press-release/hoth-therapeutics-exercises-patent-licensing-option-with-the-george-washington
https://www.nasdaq.com/press-release/emerging-markets-report%3a-a-pretty-good-month-2019-12-23
https://www.nasdaq.com/press-release/emerging-markets-report-hoth-therapeutics-on-the-fast-track-toward-delivering-eczema
https://www.nasdaq.com/press-release/hoth-therapeutics-inc.-to-present-at-the-investor-summit-on-december-17th-in
https://www.nasdaq.com/press-release/hoth-therapeutics-to-present-at-the-ld-micro-main-event-xii-2019-12-02
https://www.nasdaq.com/press-release/spherix-notes-additional-patent-coverage-granted-2019-11-27
https://www.nasdaq.com/press-release/spherix-issues-update-to-shareholders-2019-10-21
https://www.nasdaq.com/press-release/spherix-highlights-valuengine-upgrade-to-buy-rating-2019-10-17
https://www.nasdaq.com/press-release/spherix-sets-record-date-for-dividend-distribution-2019-10-11
https://www.nasdaq.com/press-release/spherix-issues-update-to-shareholders-2019-10-01
https://www.nasdaq.com/press-release/emerging-markets-report%3a-looking-beyond-skin-deep-2019-09-25
https://www.nasdaq.com/press-release/university-of-maryland-baltimore-grants-spherix-exclusive-option-to-license-anthrax
